Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.50.

AQXP has been the subject of several recent research reports. ValuEngine raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, August 20th. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. BidaskClub raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 21st. Guggenheim lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $26.00 price target for the company. in a report on Wednesday, June 27th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aquinox Pharmaceuticals in a report on Wednesday, June 27th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MYDA Advisors LLC acquired a new stake in Aquinox Pharmaceuticals during the 2nd quarter valued at $106,000. Renaissance Technologies LLC bought a new position in Aquinox Pharmaceuticals during the 2nd quarter valued at $151,000. Deutsche Bank AG boosted its stake in Aquinox Pharmaceuticals by 157.6% during the 4th quarter. Deutsche Bank AG now owns 21,878 shares of the company’s stock valued at $257,000 after acquiring an additional 13,385 shares during the last quarter. GSA Capital Partners LLP bought a new position in Aquinox Pharmaceuticals during the 1st quarter valued at $342,000. Finally, Alps Advisors Inc. boosted its stake in Aquinox Pharmaceuticals by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 31,472 shares of the company’s stock valued at $443,000 after acquiring an additional 5,471 shares during the last quarter. 73.83% of the stock is owned by institutional investors and hedge funds.

Shares of Aquinox Pharmaceuticals stock remained flat at $$2.95 during trading hours on Friday. 120,838 shares of the stock traded hands, compared to its average volume of 259,084. Aquinox Pharmaceuticals has a 52 week low of $1.96 and a 52 week high of $16.90.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Wednesday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.71. The business had revenue of $25.00 million during the quarter.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

See Also: Hedge Funds

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.